Cell-surface β-galactoside-containing glycoproteins and glycolipids

Cell-surface β-galactoside-containing glycoproteins and glycolipids are a diverse class of glycoconjugates that serve as the primary ligands for the galectin family of proteins (Vasta et al., 2012). These glycans, often characterized by the presence of N-acetyllactosamine (LacNAc) units, form a dynamic 'galectin-glycan lattice' on the cell surface that regulates the spacing, clustering, and endocytosis of critical receptors such as T-cell receptors (TCRs) and cytokine receptors (Johannes et al., 2018). In the immune system, these interactions are pivotal for modulating T-cell activation, apoptosis, and overall immune homeostasis (Thijssen et al., 2015). In pathological states like cancer and fibrosis, aberrant glycosylation leads to the overexpression of these β-galactoside structures, which galectins (particularly Galectin-1 and Galectin-3) exploit to promote immune evasion, angiogenesis, and tissue remodeling (Nabi et al., 2015). Therapeutic strategies often involve using galectin inhibitors—either carbohydrate-based mimetics or small molecules—to disrupt the binding between galectins and these cell-surface glycans, thereby restoring immune function or halting fibrotic progression (Galecto, 2023; Galectin Therapeutics, 2023).

Other names

Galectin ligandsβ-galactoside-containing glycoconjugatesGalectin-binding glycansPoly-N-acetyllactosamine structuresGalectin-glycan lattice components

These molecules serve as ligands for the galectin family of proteins; therapeutic agents typically act as competitive inhibitors of galectins (such as Galectin-1 or Galectin-3), binding to their carbohydrate-recognition domains (CRD) to prevent the cross-linking of these cell-surface β-galactoside-containing glycoconjugates and the subsequent formation of the galectin-glycan lattice (Johannes et al., 2018; Thijssen et al., 2015).